<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Exploratory IND Template - VPT-101</title>
    <meta name="description" content="Exploratory IND template for vault protein therapies">
    
    <!-- Open Graph Meta Tags -->
    <meta property="og:title" content="Exploratory IND Template - VPT-101">
    <meta property="og:description" content="Exploratory IND template for vault protein therapies">
    <meta property="og:type" content="website">
    <meta property="og:url" content="https://bigrob7605.github.io/VPT-101/regulatory/exploratory_ind_template.html">
    
    <!-- Favicon -->
    <link rel="icon" type="image/x-icon" href="data:image/svg+xml,<svg xmlns='http://www.w3.org/2000/svg' viewBox='0 0 100 100'><text y='.9em' font-size='90'>üß¨</text></svg>">
    
    <style>
        * {
            margin: 0;
            padding: 0;
            box-sizing: border-box;
        }

        :root {
            --primary: #2563eb;
            --primary-dark: #1d4ed8;
            --secondary: #10b981;
            --accent: #f59e0b;
            --dark: #1f2937;
            --light: #f8fafc;
            --gray: #6b7280;
            --border: #e5e7eb;
        }

        body {
            font-family: 'Inter', -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, sans-serif;
            line-height: 1.6;
            color: var(--dark);
            background: linear-gradient(135deg, #667eea 0%, #764ba2 100%);
            min-height: 100vh;
        }

        .container {
            max-width: 1200px;
            margin: 0 auto;
            padding: 0 20px;
        }

        /* Header */
        .header {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            position: fixed;
            top: 0;
            left: 0;
            right: 0;
            z-index: 1000;
            box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
        }

        .nav {
            display: flex;
            justify-content: space-between;
            align-items: center;
            padding: 1rem 0;
        }

        .logo {
            font-size: 1.5rem;
            font-weight: 700;
            color: var(--primary);
            text-decoration: none;
        }

        .nav-links {
            display: flex;
            gap: 2rem;
            list-style: none;
        }

        .nav-links a {
            text-decoration: none;
            color: var(--dark);
            font-weight: 500;
            transition: color 0.3s ease;
        }

        .nav-links a:hover {
            color: var(--primary);
        }

        /* Main Content */
        .main {
            padding: 120px 0 80px;
        }

        .content {
            background: rgba(255, 255, 255, 0.95);
            backdrop-filter: blur(10px);
            border-radius: 16px;
            padding: 3rem;
            margin: 2rem 0;
            box-shadow: 0 20px 25px -5px rgba(0, 0, 0, 0.1);
        }

        h1 {
            color: var(--primary);
            font-size: 2.5rem;
            margin-bottom: 1rem;
            text-align: center;
        }

        h2 {
            color: var(--primary);
            font-size: 1.8rem;
            margin: 2rem 0 1rem;
            border-bottom: 2px solid var(--primary);
            padding-bottom: 0.5rem;
        }

        h3 {
            color: var(--primary-dark);
            font-size: 1.4rem;
            margin: 1.5rem 0 0.5rem;
        }

        h4 {
            color: var(--dark);
            font-size: 1.2rem;
            margin: 1rem 0 0.5rem;
        }

        p {
            margin: 1rem 0;
            color: var(--dark);
        }

        ul, ol {
            margin: 1rem 0;
            padding-left: 2rem;
        }

        li {
            margin: 0.5rem 0;
        }

        .warning {
            background: #fef3c7;
            border: 1px solid #f59e0b;
            border-radius: 8px;
            padding: 1rem;
            margin: 1rem 0;
        }

        .info {
            background: #dbeafe;
            border: 1px solid #3b82f6;
            border-radius: 8px;
            padding: 1rem;
            margin: 1rem 0;
        }

        .download-link {
            display: inline-block;
            background: var(--primary);
            color: white;
            padding: 0.75rem 1.5rem;
            border-radius: 8px;
            text-decoration: none;
            font-weight: 600;
            transition: background-color 0.3s ease;
            margin: 0.5rem 0;
        }

        .download-link:hover {
            background: var(--primary-dark);
        }

        .back-link {
            display: inline-block;
            color: var(--primary);
            text-decoration: none;
            font-weight: 600;
            margin-bottom: 2rem;
        }

        .back-link:hover {
            text-decoration: underline;
        }

        .template-section {
            background: white;
            border-radius: 12px;
            padding: 2rem;
            margin: 2rem 0;
            box-shadow: 0 4px 6px -1px rgba(0, 0, 0, 0.1);
            border: 1px solid var(--border);
        }

        pre {
            background: #f8fafc;
            border: 1px solid var(--border);
            border-radius: 8px;
            padding: 1rem;
            overflow-x: auto;
            margin: 1rem 0;
        }

        code {
            background: #f1f5f9;
            padding: 0.2rem 0.4rem;
            border-radius: 4px;
            font-family: 'Monaco', 'Menlo', 'Ubuntu Mono', monospace;
        }

        @media (max-width: 768px) {
            .nav-links {
                display: none;
            }
            
            .content {
                padding: 2rem;
                margin: 1rem 0;
            }
            
            h1 {
                font-size: 2rem;
            }
        }
    </style>
</head>
<body>
    <header class="header">
        <nav class="nav container">
            <a href="../index.html" class="logo">VPT-101</a>
            <ul class="nav-links">
                <li><a href="../index.html">Home</a></li>
                <li><a href="../dashboard.html">Dashboard</a></li>
                <li><a href="../industry_express_lane.html">Industry</a></li>
                <li><a href="../docs/">Documentation</a></li>
            </ul>
        </nav>
    </header>

    <main class="main">
        <div class="container">
            <a href="index.html" class="back-link">‚Üê Back to Regulatory Templates</a>
            
            <div class="content">
                <h1>üî¨ Exploratory IND Template for VPT-101 Micro-dose Study</h1>
                
                <div class="warning">
                    <strong>‚ö†Ô∏è Important Disclaimers:</strong>
                    <ul>
                        <li>This is a template only - Must be customized for specific applications</li>
                        <li>Legal review required - Consult with regulatory experts before submission</li>
                        <li>FDA guidance - Follow current FDA guidelines and requirements</li>
                        <li>Professional assistance - Consider hiring regulatory consultants for complex submissions</li>
                    </ul>
                </div>

                <h2>üìã FDA Guidance Compliance</h2>
                <p>This template follows FDA guidance for Exploratory IND studies (14-day review timeline).</p>

                <h2>üî¨ Study Design: Single IV Micro-dose (0.01 mg kg‚Åª¬π)</h2>

                <h3>Primary Objectives</h3>
                <ol>
                    <li><strong>Vault PK Assessment</strong>: LC-MS/MS quantification of unique peptide tag</li>
                    <li><strong>Proof-of-Mechanism</strong>: Real-time Raman spectroscopy of serum PET fragments</li>
                    <li><strong>Safety Profile</strong>: Sub-pharmacologic dose safety evaluation</li>
                </ol>

                <h3>Study Population</h3>
                <ul>
                    <li><strong>Sample Size</strong>: 6 healthy volunteers</li>
                    <li><strong>Age Range</strong>: 18-65 years</li>
                    <li><strong>Health Status</strong>: No known plastic exposure, normal liver/kidney function</li>
                    <li><strong>Exclusion Criteria</strong>: Pregnancy, recent plastic surgery, known PET allergies</li>
                </ul>

                <h2>üìä Endpoints</h2>

                <h3>Primary Endpoints</h3>
                <ul>
                    <li><strong>Vault PK</strong>: Plasma concentration-time curve (0-24h)</li>
                    <li><strong>PET Degradation</strong>: Raman spectroscopy at 0, 2, 4, 8, 12, 24h</li>
                    <li><strong>Safety</strong>: Vital signs, CBC, chemistry panel, urinalysis</li>
                </ul>

                <h3>Secondary Endpoints</h3>
                <ul>
                    <li><strong>Biodistribution</strong>: Tissue sampling (optional biopsies)</li>
                    <li><strong>Metabolite Analysis</strong>: LC-MS/MS of degradation products</li>
                    <li><strong>Immune Response</strong>: Cytokine panel, complement activation</li>
                </ul>

                <h2>üíâ Dosing Protocol</h2>
                <pre><code>Day 1: Baseline measurements
Day 2: Single IV infusion (0.01 mg kg‚Åª¬π over 30 min)
Days 3-8: Daily monitoring
Day 14: Final safety assessment</code></pre>

                <h2>üõ°Ô∏è Safety Monitoring</h2>
                <ul>
                    <li><strong>Real-time</strong>: Continuous ECG, pulse oximetry during infusion</li>
                    <li><strong>Daily</strong>: Vital signs, adverse event assessment</li>
                    <li><strong>Weekly</strong>: Laboratory safety panels</li>
                    <li><strong>Emergency</strong>: Immediate discontinuation protocol</li>
                </ul>

                <h2>üìà Statistical Analysis</h2>
                <ul>
                    <li><strong>Sample Size</strong>: 6 subjects (pilot study)</li>
                    <li><strong>Primary Analysis</strong>: Descriptive statistics</li>
                    <li><strong>Safety Analysis</strong>: Incidence of adverse events</li>
                    <li><strong>PK Analysis</strong>: Non-compartmental modeling</li>
                </ul>

                <h2>‚è∞ Regulatory Timeline</h2>
                <ul>
                    <li><strong>IND Submission</strong>: Day 0</li>
                    <li><strong>FDA Review</strong>: 14 days (Exploratory IND)</li>
                    <li><strong>Study Start</strong>: Day 15 (if approved)</li>
                    <li><strong>Interim Report</strong>: Day 30</li>
                    <li><strong>Final Report</strong>: Day 60</li>
                </ul>

                <h2>üìã Required Documentation</h2>

                <h3>Pre-IND Meeting Request</h3>
                <ul>
                    <li>Briefing document (5 pages max)</li>
                    <li>Study protocol summary</li>
                    <li>Toxicology data summary</li>
                    <li>Manufacturing information</li>
                </ul>

                <h3>IND Application Components</h3>
                <ol>
                    <li><strong>Form FDA 1571</strong></li>
                    <li><strong>Form FDA 1572</strong> (Investigator's Statement)</li>
                    <li><strong>Protocol</strong>: Complete study protocol</li>
                    <li><strong>Chemistry, Manufacturing, and Controls (CMC)</strong></li>
                    <li><strong>Nonclinical Pharmacology/Toxicology</strong></li>
                    <li><strong>Previous Human Experience</strong></li>
                    <li><strong>Additional Information</strong></li>
                </ol>

                <h3>CMC Requirements</h3>
                <ul>
                    <li><strong>Drug Substance</strong>: Vault nanoparticle characterization</li>
                    <li><strong>Drug Product</strong>: Formulation, stability, sterility</li>
                    <li><strong>Manufacturing</strong>: GMP-compliant production</li>
                    <li><strong>Quality Control</strong>: Release specifications</li>
                </ul>

                <h3>Toxicology Package</h3>
                <ul>
                    <li><strong>Acute Toxicity</strong>: Single-dose studies (2 species)</li>
                    <li><strong>Repeat-Dose</strong>: 7-day studies (1 species)</li>
                    <li><strong>Genotoxicity</strong>: Ames test, micronucleus</li>
                    <li><strong>Safety Pharmacology</strong>: Cardiovascular, respiratory, CNS</li>
                </ul>

                <h2>‚ö†Ô∏è Risk Mitigation</h2>

                <h3>Known Risks</h3>
                <ul>
                    <li><strong>Allergic Reaction</strong>: Pre-treatment with antihistamines</li>
                    <li><strong>Infusion Reaction</strong>: Slow infusion rate, monitoring</li>
                    <li><strong>Off-target Effects</strong>: Negative control vaults included</li>
                </ul>

                <h3>Unknown Risks</h3>
                <ul>
                    <li><strong>Long-term Effects</strong>: Limited by micro-dose design</li>
                    <li><strong>Immune Response</strong>: Monitoring for cytokine release</li>
                    <li><strong>Biodistribution</strong>: Tissue sampling for analysis</li>
                </ul>

                <h2>‚úÖ Success Criteria</h2>
                <ul>
                    <li><strong>Safety</strong>: No serious adverse events</li>
                    <li><strong>PK</strong>: Detectable vault levels in plasma</li>
                    <li><strong>Mechanism</strong>: PET degradation confirmed by Raman</li>
                    <li><strong>Regulatory</strong>: FDA approval for full-dose study</li>
                </ul>

                <h2>üöÄ Next Steps</h2>
                <ol>
                    <li><strong>Pre-IND Meeting</strong>: Schedule with FDA</li>
                    <li><strong>Manufacturing</strong>: Scale-up GMP production</li>
                    <li><strong>Toxicology</strong>: Complete required studies</li>
                    <li><strong>IND Submission</strong>: Submit complete package</li>
                    <li><strong>Study Initiation</strong>: Begin recruitment</li>
                </ol>

                <h2>üìû Contact Information</h2>
                <ul>
                    <li><strong>Sponsor</strong>: VPT-101 Consortium</li>
                    <li><strong>Principal Investigator</strong>: [To be determined]</li>
                    <li><strong>Regulatory Affairs</strong>: screball7605@aol.com</li>
                    <li><strong>FDA Contact</strong>: [Division of Clinical Trial Design and Analysis]</li>
                </ul>

                <div class="info">
                    <strong>üìã Complete Template:</strong> This is a condensed version of the template. For the complete exploratory IND template with all sections and detailed guidance, download the full Markdown version.
                </div>

                <div style="text-align: center; margin: 2rem 0;">
                    <a href="exploratory_ind_template.md" class="download-link" download>üì• Download Complete Template (Markdown)</a>
                </div>

                <h2>üîó Additional Resources</h2>
                
                <ul>
                    <li><a href="https://www.fda.gov/drugs/development-resources/investigational-new-drug-ind-application" target="_blank">FDA IND Application Guide</a></li>
                    <li><a href="https://www.fda.gov/drugs/development-resources/chemistry-manufacturing-and-controls-cmc" target="_blank">FDA CMC Guidelines</a></li>
                    <li><a href="https://www.fda.gov/drugs/development-resources/investigators-brochure" target="_blank">Investigator's Brochure Requirements</a></li>
                    <li><a href="../docs/" target="_blank">VPT-101 Documentation</a></li>
                </ul>

                <h2>üí¨ Community Support</h2>
                
                <p>Need help with regulatory submissions? Connect with our community:</p>
                
                <ul>
                    <li><strong>Email:</strong> screball7605@aol.com</li>
                    <li><strong>Matrix:</strong> #vault-detox:matrix.org</li>
                    <li><strong>Documentation:</strong> <a href="../docs/">VPT-101 Docs</a></li>
                </ul>

                <div class="warning">
                    <strong>‚ö†Ô∏è Disclaimer:</strong> This template is provided under CC0 1.0 Universal license. Modify as needed for your specific study requirements. Always consult with qualified regulatory professionals before submitting to any regulatory authority.
                </div>
            </div>
        </div>
    </main>
</body>
</html> 